202 related articles for article (PubMed ID: 21885207)
21. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
[TBL] [Abstract][Full Text] [Related]
22. Post-mastectomy radiotherapy is associated with improved overall survival in T3N0 patients who do not receive chemotherapy.
Almahariq MF; Quinn TJ; Siddiqui ZA; Thompson AB; Jawad MS; Chen PY; Gustafson GS; Dilworth JT
Radiother Oncol; 2020 Apr; 145():229-237. PubMed ID: 32065903
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
Zhao JM; An Q; Sun CN; Li YB; Qin ZL; Guo H; Zeng X; Zhang YT; Wei LL; Han N; Sun SC; Zhang N
Breast Cancer; 2021 Mar; 28(2):298-306. PubMed ID: 32940902
[TBL] [Abstract][Full Text] [Related]
24. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA
Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826
[TBL] [Abstract][Full Text] [Related]
25. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
26. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy.
Sharma R; Bedrosian I; Lucci A; Hwang RF; Rourke LL; Qiao W; Buchholz TA; Kronowitz SJ; Krishnamurthy S; Babiera GV; Gonzalez-Angulo AM; Meric-Bernstam F; Mittendorf EA; Hunt KK; Kuerer HM
Ann Surg Oncol; 2010 Nov; 17(11):2899-908. PubMed ID: 20443145
[TBL] [Abstract][Full Text] [Related]
27. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era.
Miyashita M; Tada H; Suzuki A; Watanabe G; Hirakawa H; Amari M; Kakugawa Y; Kawai M; Furuta A; Sato K; Yoshida R; Ebata A; Sasano H; Jingu K; Ohuchi N; Ishida T
Surg Oncol; 2017 Jun; 26(2):163-170. PubMed ID: 28577722
[TBL] [Abstract][Full Text] [Related]
28. Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
Tan CF; Wang J; Zhong XR; Dai ZL; Xiang ZZ; Zeng YY; Wei XY; Xu NY; Liu L
Breast Cancer Res Treat; 2024 Jul; 206(1):45-56. PubMed ID: 38616207
[TBL] [Abstract][Full Text] [Related]
29. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
Cheng SH; Horng CF; Clarke JL; Tsou MH; Tsai SY; Chen CM; Jian JJ; Liu MC; West M; Huang AT; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1401-9. PubMed ID: 16472935
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
Stauder MC; Caudle AS; Allen PK; Shaitelman SF; Smith BD; Hoffman KE; Buchholz TA; Chavez-Macgregor M; Hunt KK; Meric-Bernstam F; Woodward WA
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):637-44. PubMed ID: 27681760
[TBL] [Abstract][Full Text] [Related]
31. Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy.
Meattini I; Cecchini S; Di Cataldo V; Saieva C; Francolini G; Scotti V; Bonomo P; Mangoni M; Greto D; Nori J; Orzalesi L; Casella D; Simoncini R; Fambrini M; Bianchi S; Livi L
Biomed Res Int; 2014; 2014():719175. PubMed ID: 25045694
[TBL] [Abstract][Full Text] [Related]
32. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
[TBL] [Abstract][Full Text] [Related]
33. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
Fodor J; Polgár C; Major T; Németh G
Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
[TBL] [Abstract][Full Text] [Related]
34. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
35. Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival.
Woodward WA; Truong PT; Yu TK; Tereffe W; Oh J; Perkins G; Strom E; Meric-Bernstam F; Gonzalez-Angulo AM; Speers C; Ragaz J; Buchholz TA
Breast Cancer Res Treat; 2010 Sep; 123(2):597-605. PubMed ID: 20306128
[TBL] [Abstract][Full Text] [Related]
36. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
Woodward WA; Strom EA; Tucker SL; Katz A; McNeese MD; Perkins GH; Buzdar AU; Hortobagyi GN; Hunt KK; Sahin A; Meric F; Sneige N; Buchholz TA
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):336-44. PubMed ID: 12957243
[TBL] [Abstract][Full Text] [Related]
37. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
[TBL] [Abstract][Full Text] [Related]
39. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574
[TBL] [Abstract][Full Text] [Related]
40. The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy.
Keruakous AR; Sadek BT; Shenouda MN; Niemierko A; Abi Raad RF; Specht M; Smith BL; Taghian AG
Breast Cancer Res Treat; 2014 Jul; 146(2):365-70. PubMed ID: 24952906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
